Personalis Price Target | Analysis, Price & Growth Outlook

Personalis

NasdaqGM:PSNL

$ 6,02

$-0,07 (-1,15%)

6,02 $

$-0,07 (-1,15%)

End-of-day quote: 04/10/2026

Personalis Stock Value

Analysts currently rate NasdaqGM:PSNL as Buy.

Buy

Personalis Company Info

EPS Growth 5Y

5,38%

Market Cap

$0,63 B

Long-Term Debt

$0,00 B

Short Interest

8,87%

Quarterly earnings

05/05/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

2011

Industry

Health Care

Country

United States

ISIN Number

US71535D1063

Website

http://www.personalis.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$11,00

82.72%

Last Update: 04/11/2026

Analysts: 7

Highest Price Target $13,00

Average Price Target $11,00

Lowest Price Target $10,00

In the last five quarters, Personalis’s Price Target has risen from $2,76 to $4,45 - a 61,23% increase. Six analysts predict that Personalis’s share price will increase in the coming year, reaching $11,00. This would represent an increase of 82,72%.

Top growth stocks in the health care sector (5Y.)

What does Personalis do?

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics. The company focuses on delivering personalized medicine solutions, particularly in the field of oncology. Business Segments The company operates primarily in the biotechnology sector, with a focus on genomic sequencing and data analysis services. The company’s business segments include clinical services, research and development, and collaborations with pharmaceutical companies. The clinical services segment pro...

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics. The company focuses on delivering personalized medicine solutions, particularly in the field of oncology.

Business Segments

The company operates primarily in the biotechnology sector, with a focus on genomic sequencing and data analysis services. The company’s business segments include clinical services, research and development, and collaborations with pharmaceutical companies. The clinical services segment provides genomic sequencing and analysis for cancer patients, enabling healthcare providers to make informed treatment decisions based on individual genetic profiles. This segment is critical for the advancement of the company’s medicine, as it allows for the identification of specific mutations and biomarkers that can influence treatment efficacy.

The research and development segment is dedicated to the continuous improvement of the company’s sequencing technologies and analytical capabilities. This segment focuses on developing new methodologies and applications for genomic data, ensuring that the company remains at the forefront of innovation in the field.

Collaborations with pharmaceutical companies form another essential segment of the company business. The company partners with leading biopharmaceutical firms to support drug development and clinical trials. These collaborations enable the company to provide valuable genomic insights that can accelerate the development of new therapies and improve clinical trial outcomes.

Business Strategy

The company employs a multifaceted business strategy aims at establishing itself as a leader in the field of precision medicine. The company’s strategy focuses on innovation, collaboration, and market expansion. By investing in research and development, the company seeks to enhance its genomic sequencing technologies and analytical capabilities, ensuring that it remains at the cutting edge of the biotechnology industry.

Collaboration is a cornerstone of the company’s strategy. By partnering with pharmaceutical companies and academic institutions, the company aims to leverage external expertise and resources to accelerate the development of new therapies and improve clinical trial outcomes. These collaborations enhance the company’s service offerings and expand its market presence and credibility within the industry.

Market expansion is another critical component of the company’s strategy. The company focuses on increasing its customer base by targeting healthcare providers, research institutions, and pharmaceutical companies. The company aims to penetrate new markets and geographic regions, thereby broadening its reach and enhancing its growth potential.

Additionally, the company is committed to educating healthcare professionals and stakeholders about the benefits of genomic sequencing and personalized medicine. By raising awareness and demonstrating the value of its services, the company aims to drive adoption and establish itself as a trusted partner in the healthcare ecosystem.

Products and Services

The company offers a range of products and services centered around genomic sequencing and data analysis. The company’s primary offerings include comprehensive genomic profiling, which provides detailed insights into the genetic makeup of tumors. This service is essential for identifying actionable mutations and biomarkers that can inform treatment decisions for cancer patients.

The company also provides advanced data analysis services, utilizing its proprietary algorithms and analytical tools to interpret complex genomic data. These services enable healthcare providers to gain a deeper understanding of a patient’s cancer and tailor treatment plans accordingly.

In addition to its core genomic sequencing services, the company offers support for clinical trials, providing genomic insights that can enhance trial design and patient stratification. The company collaborates with pharmaceutical companies to deliver customized genomic solutions that align with specific research objectives.

Furthermore, the company is dedicated to continuous innovation, regularly updating its service offerings to incorporate the latest advancements in genomic technology and analysis. This commitment to innovation ensures that the company remains a leader in the field of precision medicine.

Geographical Markets Served

The company serves a diverse range of geographical markets, primarily focuses on North America and expanding its presence in international markets. The company’s services are utilized by healthcare providers, research institutions, and pharmaceutical companies across various regions.

Customers

The company serves a diverse range of customers, including healthcare providers, research institutions, and pharmaceutical companies. The company’s customer base includes leading hospitals, cancer treatment centers, and academic research organizations that utilize its genomic sequencing and data analysis services to inform treatment decisions and support clinical research.

Sales and Marketing

The company employs a multifaceted approach to sales and marketing, focusing on building relationships with healthcare providers, research institutions, and pharmaceutical companies. The company utilizes a combination of direct sales efforts, partnerships, and collaborations to reach its target customers.

Marketing efforts are centered around educating stakeholders about the benefits of genomic sequencing and personalized medicine. The company participates in industry conferences, workshops, and seminars to showcase its services and engage with potential customers. Additionally, the company leverages digital marketing strategies to enhance its online presence and reach a broader audience.

Government Regulations

The company adheres to the regulations set forth by the U.S. Food and Drug Administration (FDA) and other relevant regulatory bodies governing the biotechnology and healthcare sectors.

History

Personalis, Inc. was founded in 2011. The company was incorporated in 2011.

Personalis Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by industry:** 1. Genomics and Diagnostics 2. Oncology 3. Biopharmaceutical Research **TOP 3 markets and their percentage shares:** 1. USA: 55% 2. Europe: 25% 3. Asia-Pacific: 15% Personalis, Inc. generates the majority of its revenue from genomics and diagnostics, particula...

At which locations are the company’s products manufactured?

**Production Site:** Menlo Park, California, USA Personalis, Inc. primarily produces its products in Menlo Park, California. The company's main laboratory is located there, responsible for the development and manufacturing of its genomic products and services. The company focuses on providing...

What strategy does Personalis pursue for future growth?

**Revenue Growth:** 8.5% (2025, estimated) **R&D Expenses:** 20% of revenue (2025, estimated) Personalis, Inc. is pursuing a growth strategy that is heavily focused on research and development (R&D) to further solidify its position in the field of personalized medicine and genomics. The c...

Which raw materials are imported and from which countries?

Sorry, but I do not have specific information about the commodities or materials that Personalis, Inc. imports, or the countries of origin of these materials. Personalis, Inc. is a company specializing in genomics and personalized medicine. Typically, companies in this sector require materials such...

How strong is the company’s competitive advantage?

**Market Share:** Estimated 5-7% in the field of personalized medicine (2026) **Research & Development:** Investments of approximately 20% of revenue in R&D (2025) **Partnerships:** Collaborations with leading pharmaceutical companies and research institutions Personalis, Inc. has made a...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 65% (estimated for 2026) **Insider Buys/Sells:** No significant transactions in the last year (estimated for 2026) The institutional investor share in Personalis, Inc. is estimated to be around 65%. This suggests that a large portion of the shares are held by maj...

What percentage market share does Personalis have?

**Market share of Personalis, Inc.:** Estimated 5% (2026) **Top competitors and their market shares:** 1. Illumina, Inc. - 25% 2. Thermo Fisher Scientific Inc. - 20% 3. Qiagen N.V. - 15% 4. Agilent Technologies, Inc. - 10% 5. Bio-Rad Laboratories, Inc. - 8% 6. Personalis, Inc. - 5% 7. Guardant Heal...

Is Personalis stock currently a good investment?

**Revenue Growth:** 8.5% (2025) **R&D Expenses:** 30% of revenue (2025) **Market Share in Genomics:** 5% (2025) Personalis, Inc. recorded a revenue growth of 8.5% in 2025, indicating solid demand for their genomics services. The company is heavily investing in research and development, with 30%...

Does Personalis pay a dividend – and how reliable is the payout?

**Dividend payment:** None (as of 2026) Personalis, Inc. currently does not pay a dividend. The company focuses on reinvesting profits into research and development as well as growing its business model. In the biotechnology industry, it is not uncommon for companies not to pay dividends, especiall...

New support ticket

Explore

Personalis Stock Value

Personalis Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Personalis do?

Personalis Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Personalis Stock Value

Personalis Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Personalis do?

Personalis Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.